TCGA-BH-A0DE-01A-11R-A115-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 79
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.520
- ANGIOGENESIS+0.410
- TGF_BETA_SIGNALING+0.410
- WNT_BETA_CATENIN_SIGNALING+0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- INFLAMMATORY_RESPONSE+0.370
- KRAS_SIGNALING_UP+0.370
- IL6_JAK_STAT3_SIGNALING+0.320
- MYOGENESIS+0.320
- ALLOGRAFT_REJECTION+0.300
Top 10 suppressed
- E2F_TARGETS-0.620
- G2M_CHECKPOINT-0.550
- MYC_TARGETS_V1-0.510
- MYC_TARGETS_V2-0.360
- GLYCOLYSIS-0.330
- DNA_REPAIR-0.300
- SPERMATOGENESIS-0.290
- MITOTIC_SPINDLE-0.260
- MTORC1_SIGNALING-0.260
- UNFOLDED_PROTEIN_RESPONSE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_ZV9Z3SY6 | pilocytic astrocytoma | — | 0.926 |
| 2 | GSM6454738 | — | A | 0.920 |
| 3 | TCGA-D8-A27I-01A-11R-A16F-07 | — | A | 0.916 |
| 4 | TCGA-AC-A3HN-01A-11R-A213-07 | — | A | 0.916 |
| 5 | TCGA-78-8648-01A-11R-2403-07 | — | cohortMD2 | 0.915 |
| 6 | SRR1797296 | — | cohortMD2 | 0.915 |
| 7 | SRR12475153 | — | — | 0.914 |
| 8 | BS_E4F1D721 | EPN | EPN Tumor | 0.913 |
| 9 | SRR8518124 | — | D | 0.912 |
| 10 | TCGA-AC-A2FO-01A-11R-A180-07 | — | A | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.520 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.410 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.410 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.390 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.370 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| MYOGENESIS | 0.320 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.280 | Idelalisib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |